TLV •
Healthcare •
Biotechnology •
Quote as of 09/10/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTLV
Market Capitalization588.11 mln
Float35.26 mln
Earnings Date11/13/2026
EPS
12.45
Robust
P / E
1.15
Deeply undervalued
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
9
/ 100
Severely lagging
Debt / Equity
0.00
Debt-free
ROE
78.54
Exceptional
Business Description
Oramed Pharmaceuticals is a drug development company focused on creating pills that deliver proteins and insulin directly through the digestive system, removing the need for injections. Its lead product, an oral insulin capsule, has advanced to late-stage clinical trials for people living with diabetes. The company also holds licensing rights to develop oral COVID-19 vaccines through a partnership with Oravax Medical. Founded in 2002 and based in New York, Oramed aims to make treatment easier and more accessible for patients worldwide.
